Paulo M. Hoff

2000–2025 年に発表

83
論文数
20,742
被引用数
62
h 指数
79
i10 指数

被引用数

Paulo M. Hoff の年別被引用数1991 年: 被引用 1 件1992 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 4 件2002 年: 被引用 24 件2003 年: 被引用 23 件2004 年: 被引用 47 件2005 年: 被引用 58 件2006 年: 被引用 64 件2007 年: 被引用 102 件2008 年: 被引用 116 件2009 年: 被引用 109 件2010 年: 被引用 150 件2011 年: 被引用 124 件2012 年: 被引用 119 件2013 年: 被引用 130 件2014 年: 被引用 141 件2015 年: 被引用 130 件2016 年: 被引用 136 件2017 年: 被引用 189 件2018 年: 被引用 168 件2019 年: 被引用 653 件2020 年: 被引用 715 件2021 年: 被引用 722 件2022 年: 被引用 489 件2023 年: 被引用 339 件2024 年: 被引用 501 件2025 年: 被引用 225 件2026 年: 被引用 4 件1993〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,656 件、この内訳の 19%中国: 引用元論文 921 件、この内訳の 10.6%イタリア: 引用元論文 693 件、この内訳の 8%イギリス: 引用元論文 484 件、この内訳の 5.6%フランス: 引用元論文 443 件、この内訳の 5.1%ドイツ: 引用元論文 427 件、この内訳の 4.9%スペイン: 引用元論文 383 件、この内訳の 4.4%日本: 引用元論文 356 件、この内訳の 4.1%オランダ: 引用元論文 303 件、この内訳の 3.5%スイス: 引用元論文 210 件、この内訳の 2.4%カナダ: 引用元論文 208 件、この内訳の 2.4%ベルギー: 引用元論文 207 件、この内訳の 2.4%
0%19%その他 27.6%

分野

  • Medicine77.4%
  • Biochemistry, Genetics and Molecular Biology17%
  • Immunology and Microbiology1.5%
  • Mathematics0.7%
  • Engineering0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他2.4%

トピック

  • Colorectal Cancer Treatments and Studies9.5%
  • Hepatocellular Carcinoma Treatment and Prognosis4.5%
  • Colorectal Cancer Surgical Treatments4.5%
  • Gastric Cancer Management and Outcomes3.4%
  • Cancer Treatment and Pharmacology3.2%
  • HER2/EGFR in Cancer Research2.9%
  • その他72%

共著者

全論文

検索で開く
  1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 被引用: 3,449

  2. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim ほか 122 名 - The Lancet Oncology 2020 被引用: 898

  3. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2018 被引用: 497

  4. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

    著者: , , , , , , , , , , - The Lancet Oncology 2018 被引用: 478

  5. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 621

  6. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karin Jordan, Andrey Meshcheryakov, Demetris Papamichail, Per Pfeiffer, Ioannis Souglakos, Serdar Turhal, Andrés Cervantes - Annals of Oncology 2012 被引用: 1,534

  7. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 被引用: 526

  8. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

    著者: , , , , , , , , , , - Gastric Cancer 2022 被引用: 57

  9. Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases

    著者: , , , , , , , , , , , , , , - Journal of Clinical Oncology 2006 被引用: 1,296

  10. Chronic Oxaliplatin Resistance Induces Epithelial-to-Mesenchymal Transition in Colorectal Cancer Cell Lines

    著者: , , , , , , , , , - Clinical Cancer Research 2006 被引用: 526

  11. Trends in clinical profiles, organ support use and outcomes of patients with cancer requiring unplanned ICU admission: a multicenter cohort study

    著者: , , , , , , , , , , , , , , , , , , , , - Intensive Care Medicine 2020 被引用: 84

  12. Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

    著者: , , , , , , , - Journal of Clinical Oncology 2009 被引用: 271

  13. Oxaliplatin-related thrombocytopenia

    著者: , , , , - Annals of Oncology 2012 被引用: 121

  14. Irinotecan in the treatment of colorectal cancer

    著者: , , - Cancer Treatment Reviews 2006 被引用: 236

  15. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer

    著者: , , , , , , - JAMA Oncology 2015 被引用: 161

  16. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel J. Sargent, Aimery de Gramont, John Zalcberg, The Fondation Aide et Recherche en Cancerologie Digestive Group (ARCAD) - JNCI Journal of the National Cancer Institute 2017 被引用: 144

  17. Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia

    著者: , , , , , , , , , , , , , , , - Clinical Microbiology and Infection 2015 被引用: 122

  18. Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

    著者: , , , , , , , , , , , , , - Journal of Clinical Oncology 2001 被引用: 1,139

  19. Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2009 被引用: 487

  20. The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment

    著者: , , , - Current Treatment Options in Oncology 2017 被引用: 242

  21. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer

    著者: , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2016 被引用: 106

  22. Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury

    著者: , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 236

  23. Bevacizumab: overview of the literature

    著者: , , - Expert Review of Anticancer Therapy 2012 被引用: 98

  24. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin

    著者: , , , , , , , , , , , , , , , , , - Annals of Oncology 2002 被引用: 524